The Patent Finder

Prelude Therapeutics Incorporated

16 patents currently held · Updated Nov 18, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 3 name spellings.

0
Ending by 2030
Aug 2038
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Dec 13 to 27, 2026 · next Dec 13
  • 1 fee due Jan 18, 2027
    The maintenance fee for BRM Targeting Compounds and Associated Methods of Use (US 11,702,423) comes due Jan 18, 2027. Unpaid by Jul 19, 2027, it lapses early.
  • 1 fee due Aug 25, 2027
    The maintenance fee for Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) (US 10,570,140) comes due Aug 25, 2027. Unpaid by Feb 25, 2028, it lapses early.
  • 1 fee due Sep 26, 2027
    The maintenance fee for CDK inhibitors and their use as pharmaceuticals (US 11,939,340) comes due Sep 26, 2027. Unpaid by Mar 27, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 20, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 10,570,140Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,524,962Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5)
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,711,007Selective Inhibitors of Protein Arginine Methyltransferase 5 (PRMT5)
In force
 · Medium confidence
In forceMedium confidence
US 11,254,683Selective Inhibitors of Protein Arginine Methyltransferase 5 (PRMT5)
In force
 · Medium confidence
In forceMedium confidence
US 12,440,506Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)
In force
 · High confidence
In forceHigh confidence
US 12,459,950Selective Inhibitors of Protein Arginine Methyltransferase 5 (PRMT5)
In force
 · Medium confidence
In forceMedium confidence
US 11,673,893CDK inhibitors and their use as pharmaceuticals
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,622,970BCL-2 Inhibitors and Their Use as Pharmaceuticals
In force
 · High confidence
In forceHigh confidence
US 11,702,423BRM Targeting Compounds and Associated Methods of Use
In force
 · High confidence
In forceHigh confidence
US 11,685,744CDK Inhibitors And Their Use As Pharmaceuticals
In force
 · High confidence
In forceHigh confidence
10 of 16 patents shown.
Pro members see all 16.
Pro members: see all 16 patents
Also on record, not counted in the 16: 5 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

19 pending · 2 abandoned · 16 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited